Evidence map›Paper›PMID 34503110›Full record

ArticleCancers2021

Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition.

Eugenia Roupakia, Evangelia Chavdoula, Georgia Karpathiou, Giannis Vatsellas, Dimitrios Chatzopoulos, Angeliki Mela, Jennifer M Gillette, Katharina Kriegsmann, Mark Kriegsmann, Anna Batistatou and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Eugenia RoupakiaLaboratory of Biology, School of Medicine, Faculty of Health Sciences, Institute of Biosciences, University Research Centre, University of Ioannina, University Campus, 45110 Ioannina, Greece.
Evangelia ChavdoulaBiomedical Research Division, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, University of Ioannina Campus, 45115 Ioannina, Greece.
Georgia KarpathiouLaboratory of Pathology, School of Medicine, Faculty of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-0864-935X
Giannis VatsellasBiomedical Research Foundation, Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.ORCID 0000-0002-1631-1060
Dimitrios ChatzopoulosBiomedical Research Foundation, Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.
Angeliki MelaDepartment of Pathology and Cell Biology Columbia University Medical Center, Irving Comprehensive Cancer Research Center, Columbia University, New York, NY 10032, USA.
Jennifer M GilletteDepartment of Pathology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
Katharina KriegsmannDepartment of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Mark KriegsmannInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-7319-3646
Anna BatistatouLaboratory of Pathology, School of Medicine, Faculty of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Anna GoussiaLaboratory of Pathology, School of Medicine, Faculty of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Kenneth B MarcuBiomedical Research Foundation, Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.ORCID 0000-0003-2927-5430
Emmanouil KarterisDivision of Biosciences, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, Middlesex, London UB8 PH, UK.
Apostolos KlinakisBiomedical Research Foundation, Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.
Evangelos KolettasLaboratory of Biology, School of Medicine, Faculty of Health Sciences, Institute of Biosciences, University Research Centre, University of Ioannina, University Campus, 45110 Ioannina, Greece.ORCID 0000-0002-5820-487X
University of Ioannina · GRAcademy of Athens · GRHeidelberg University · DEBrunel University of London · GBColumbia University Irving Medical Center · USUniversity of New Mexico · US

Funding

Functional Role of Tetraspanin CD82 in Hematopoietic Stem Cell InteractionsR01HL122483 · NHLBI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Jennifer Gillette · 2015 to 2026
$4.2M
FONDATION SANTÉ N/AHellenic Ministry of Development and Investments - EU ARABAT MIS5002469Institute of Molecular Biology and Biotechnology, FORTH Internal grantNHLBI NIH HHS R01 HL122483Stavros Niarchos Foundation ARCHERSUniversity of Ioannina Research Committee Internal grant
6 · The paper itself

Abstract

backgroundThe development of non-small cell lung cancer (NSCLC) involves the progressive accumulation of genetic and epigenetic changes. These include somatic oncogenic

methodsHuman NSCLC cells were used to knock-down RelA/p65 (RelA/p65

resultsRelA/p65

conclusionsCanonical NF-κB signalling promotes NSCLC, in part, by downregulating the metastasis suppressor CD82/KAI1 which inhibits cell migration, EMT and tumour growth.

Indexed as

CD82cell migrationEMThuman NSCLC modelsintegrin signallingNF-κB RelA/p65RNA-seq

Identifiers

PMID34503110
PMCPMC8428346
OpenAlexW3193850084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.